These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34507680)

  • 21. Meta-analysis of efficacy and safety of pembrolizumab for the treatment of advanced or recurrent cervical cancer.
    Zhang X; Yin WJ; Zhang AL; Zhang XX; Ding LJ; Zhang J; He ST; Yan JP
    J Obstet Gynaecol; 2024 Dec; 44(1):2390564. PubMed ID: 39150330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Total laparoscopic pelvic exenteration for a laterally recurrent cervical carcinoma with a vesicovaginal fistula that developed after concurrent chemoradiotherapy.
    Kanao H; Aoki Y; Hisa T; Takeshima N
    Gynecol Oncol; 2017 Aug; 146(2):438-439. PubMed ID: 28576262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of chemotherapy on patients with recurrent cervical cancer previously treated with concurrent chemoradiotherapy: a retrospective multicenter survey in Japan.
    Tokunaga H; Nakanishi T; Iwata T; Aoki D; Saito T; Nagase S; Takahashi F; Yaegashi N; Watanabe Y
    Int J Clin Oncol; 2015 Jun; 20(3):561-5. PubMed ID: 25022787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience.
    Okazawa M; Mabuchi S; Isohashi F; Suzuki O; Yoshioka Y; Sasano T; Ohta Y; Kamiura S; Ogawa K; Kimura T
    Int J Gynecol Cancer; 2013 Mar; 23(3):567-75. PubMed ID: 23385284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of symptomatic brain metastases after chemoradiotherapy for stage III non-small cell lung cancer: Does the type of chemotherapy regimen matter?
    Hendriks LEL; Brouns -JWM; Amini M; Uyterlinde W; Wijsman R; Bussink J; Biesma B; Oei SB; Stigt JA; Bootsma GP; Belderbos JSA; De Ruysscher DKM; Van den Heuvel MM; Dingemans AC
    Lung Cancer; 2016 Nov; 101():68-75. PubMed ID: 27794410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrating Chemotherapy in the Management of Cervical Cancer: A Critical Appraisal.
    Kumar L; Gupta S
    Oncology; 2016; 91 Suppl 1():8-17. PubMed ID: 27464068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Daily low-dose Cisplatin-based concurrent chemoradiotherapy for the treatment of cervical cancer in patients 70 years or older.
    Hanawa S; Mitsuhashi A; Usui H; Yamamoto N; Watanabe-Nemoto M; Nishikimi K; Uehara T; Tate S; Uno T; Shozu M
    Int J Gynecol Cancer; 2015 Jun; 25(5):891-6. PubMed ID: 25811592
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01).
    Lee YG; Kang EJ; Keam B; Choi JH; Kim JS; Park KU; Lee KE; Kwon JH; Lee KW; Kim MK; Ahn HK; Shin SH; Kim HR; Kim SB; Yun HJ
    BMC Cancer; 2020 Aug; 20(1):813. PubMed ID: 32854649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of salvage therapies for isolated para-aortic lymph node recurrence in patients with uterine cervical cancer after definitive treatment.
    Kubota H; Tsujino K; Sulaiman NS; Sekii S; Matsumoto Y; Ota Y; Soejima T; Yamaguchi S; Sasaki R
    Radiat Oncol; 2019 Dec; 14(1):236. PubMed ID: 31878944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cervical adenocarcinoma, a novel combination chemotherapy with mitomycin C, etoposide, and cisplatin for advanced or recurrent disease.
    Umesaki N; Izumi R; Fushiki H; Hasegawa K; Kono I; Nishida M; Noguchi H; Okuda H; Sugimori H; Takizawa K; Udagawa Y; Yamamoto K; Tanaka T; Noda K
    Gynecol Oncol; 1999 Oct; 75(1):142-4. PubMed ID: 10502441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cervical cancer with paraaortic involvement: do patients truly benefit from tailored chemoradiation therapy? A retrospective study on 8 French centers.
    Chantalat E; Vidal F; Leguevaque P; Lepage B; Mathevet P; Deslandres M; Motton S
    Eur J Obstet Gynecol Reprod Biol; 2015 Oct; 193():118-22. PubMed ID: 26295788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concurrent chemoradiotherapy with or without adjuvant chemotherapy in intermediate and locoregionally advanced nasopharyngeal carcinoma.
    Zhang W; Dou H; Lam C; Liu J; Zhou J; Liu Y; Wang X
    Tumour Biol; 2013 Jun; 34(3):1729-36. PubMed ID: 23436047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapy-free interval has prognostic value in patients with recurrent cervical cancer treated with chemotherapy following definitive concurrent chemoradiotherapy.
    Kozaki M; Sakuma S; Kudaka W; Kinjyo Y; Taira Y; Arakaki Y; Shimoji Y; Nakasone T; Nakamoto T; Wakayama A; Ooyama T; Aoki Y
    Arch Gynecol Obstet; 2017 Nov; 296(5):997-1003. PubMed ID: 28884382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer.
    Katanyoo K; Sanguanrungsirikul S; Manusirivithaya S
    Gynecol Oncol; 2012 May; 125(2):292-6. PubMed ID: 22293041
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy.
    Huang YT; Wang CC; Tsai CS; Lai CH; Chang TC; Chou HH; Lee SP; Hong JH
    Int J Radiat Oncol Biol Phys; 2012 Oct; 84(2):420-7. PubMed ID: 22365621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Curative chemoradiotherapy in patients with stage IVB cervical cancer presenting with paraortic and left supraclavicular lymph node metastases.
    Kim JY; Kim JY; Kim JH; Yoon MS; Kim J; Kim YS
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):741-7. PubMed ID: 22898382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
    Sun JM; Shen L; Shah MA; Enzinger P; Adenis A; Doi T; Kojima T; Metges JP; Li Z; Kim SB; Cho BC; Mansoor W; Li SH; Sunpaweravong P; Maqueda MA; Goekkurt E; Hara H; Antunes L; Fountzilas C; Tsuji A; Oliden VC; Liu Q; Shah S; Bhagia P; Kato K;
    Lancet; 2021 Aug; 398(10302):759-771. PubMed ID: 34454674
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant therapy after radical surgery for stage IB-IIB cervical adenocarcinoma with risk factors.
    Seki T; Tanabe H; Nagata C; Suzuki J; Suzuki K; Takano H; Isonishi S; Ochiai K; Takakura S; Okamoto A
    Jpn J Clin Oncol; 2017 Jan; 47(1):32-38. PubMed ID: 27677664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concurrent chemoradiotherapy with paclitaxel and cisplatin for adenocarcinoma of the cervix.
    Nagai Y; Toita T; Wakayama A; Nakamoto T; Ooyama T; Tokura A; Inamine M; Kudaka W; Murayama S; Aoki Y
    Anticancer Res; 2012 Apr; 32(4):1475-9. PubMed ID: 22493388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pembrolizumab in recurrent advanced cervical squamous carcinoma.
    Martínez P; Del Campo JM
    Immunotherapy; 2017 May; 9(6):467-470. PubMed ID: 28399693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.